A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.

Paller CJ, Rudek MA, Zhou XC, Wagner WD, Hudson TS, Anders N, Hammers HJ, Dowling D, King S, Antonarakis ES, Drake CG, Eisenberger MA, Denmeade SR, Rosner GL, Carducci MA. A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. Prostate. 2015 Oct; 75(14):1518-25.

View in: PubMed

subject areas

Aged
Antineoplastic Agents, Phytogenic
Cohort Studies
Dose-Response Relationship, Drug
Follow-Up Studies
Gastrointestinal Diseases
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Plant Extracts
Prostatic Neoplasms
Vitis

authors with profiles

Tamaro Hudson

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support